Problems and Solutions in the Implementation of a Transcatheter Aortic Valve Implantation Program

pp. 14-9

Authors

  • Matías Sztejfman Department of Interventional Cardiology, Sanatorio Güemes e Instituto Médico de Alta Complejidad, Ciudad Autónoma de Buenos Aires
  • Carlos Sztejfman Department of Interventional Cardiology, Sanatorio Güemes e Instituto Médico de Alta Complejidad, Ciudad Autónoma de Buenos Aires; Full Member of the Argentine Society of Cardiology
  • Mariano Albertal Department of Interventional Cardiology and Endovascular Therapeutics, Instituto Cardiovascular de Buenos Aires, Ciudad Autónoma de Buenos Aires
  • Ramón Gómez Márquez Department of Interventional Cardiology, Sanatorio Güemes e Instituto Médico de Alta Complejidad, Ciudad Autónoma de Buenos Aires
  • Alejandro Goldsmit Department of Interventional Cardiology, Sanatorio Güemes e Instituto Médico de Alta Complejidad, Ciudad Autónoma de Buenos Aires
  • Fernando G. Chiminella Department of Interventional Cardiology, Sanatorio Güemes e Instituto Médico de Alta Complejidad, Ciudad Autónoma de Buenos Aires
  • Hernán Del Percio Department of Cardiovascular Surgery, Sanatorio Güemes, Ciudad Autónoma de Buenos Aires
  • Adriano Malusardi Department of Vascular Surgery, Instituto Médico de Alta Complejidad, Ciudad Autónoma de Buenos Aires
  • Álvaro Sosa Liprandi Department of Cardiology, Sanatorio Güemes, Ciudad Autónoma de Buenos Aires; Full Member of the Argentine Society of Cardiology
  • Marcelo Bettinotti Department of Interventional Cardiology, Sanatorio Güemes e Instituto Médico de Alta Complejidad, Ciudad Autónoma de Buenos Aires; Full Member of the Argentine Society of Cardiology

DOI:

https://doi.org/10.7775/rac.es.v81.i1.2063

Keywords:

Aortic Valve Stenosis - Endovascular Procedures - Mortality

Abstract

Background
Survival of severe symptomatic aortic valve stenosis is low in patients who are not candidates for cardiac surgery. Transcatheter aortic valve implantation (TAVI) represents an alternative for these patients. Candidates for TAVI are evaluated in our TAVI Program to determine if they are clinically eligible to request authorization of the procedure from the health coverage.


Objectives
The aim of this study was to evaluate the reasons for the exclusion of patients from the procedure and its clinical impact.


Methods
Thirty seven patients were admitted in the TAVI Program from April 2009 to August 2011.


Results
From the original 37 patients, 29 patients received treatment or were excluded: 14 patients underwent the procedure (TAVI group, 48.3%) and 15 were excluded (non TAVI group, 52.7%). In the non-TAVI group, six patients (40%) were excluded by the Program and four by their health coverage, while another five died while awaiting authorization. Population median EuroSCORE was 22% (range 10-56%) and mean age was 79±8 years. At 12 month follow-up, mortality in the TAVI group and non TAVI group was 7.1% and 33.3%, respectively (p=0.082). Overall cardiovascular mortality was 17.2%, all in the non-TAVI group.


Conclusion
More than half of the patients evaluated in a TAVI Program do not undergo the procedure in our medical setting. Medical and socioeconomic reasons influence the decision-making process to perform TAVI, with a significant mortality in untreated
patients.

Published

2025-09-23

Issue

Section

ORIGINAL ARTICLES

Most read articles by the same author(s)

1 2 3 4 5 > >>